ATYR · CIK 1339970
What aTyr Pharma, Inc. told the SEC could break it.
aTyr's disclosures reflect a clinical-stage biotech whose value is concentrated in a single program: its lead candidate efzofitimod (for sarcoidosis and interstitial lung disease), with no approved products and no guarantee it will ever be developed, approved, or commercialized. Its only source of revenue depends on collaborators performing — chiefly Kyorin, its Japan partner, where limits on Kyorin's operations could significantly delay Japanese development and put up to $155 million of additional milestone payments (plus royalties) at risk. Commercialization also hinges on FDA approval, including conditions on accepting foreign clinical-trial data, while ex-U.S. price controls and cost-containment could pressure the pricing and use of any approved product.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- revenue dependence on collaborators, especially Kyorin (Japan); $155M milestones at riskmedium
aTyr's sole source of revenue depends on collaborators performing — chiefly Kyorin, its Japan partner for efzofitimod; if Kyorin's operations are limited, Japan development could be delayed and up to $155M of additional Kyorin milestone payments (plus royalties) could be lost.
“while we have received $20.0 million in upfront and milestone payments from Kyorin to date, if Kyorin's operations are limited as a result of global geopolitical and macroeconomic conditions or other reasons, the development of efzofitimod in Japan may be significantly delayed and adversely affected, which may in turn delay or limit our receipt of any additional payments under the Kyorin Agreement.”
SEC filing →As of 2026 - clinical-stage; lead candidate efzofitimod, no approved productslow
aTyr is a clinical-stage biotech whose value is concentrated in its lead candidate efzofitimod (for sarcoidosis/ILD); it has no approved products and may never successfully develop, gain approval for or commercialize it.
“It is possible that our collaborators may be unable to obtain regulatory approval of our product candidates or successfully market and commercialize any such products for which regulatory approval is obtained.”
SEC filing →As of 2026
Regulatory & policy
- FDA approval (foreign clinical-data acceptance) and drug-pricing/cost-containmentmedium
aTyr's commercialization depends on FDA approval (with conditions on accepting foreign clinical-trial data run in the US/Europe/Brazil/Japan) and faces ex-US price controls and cost-containment that could pressure the pricing and usage of its products.
“in cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Kyorin Pharmaceutical Co., Ltd.
“For the years ended December 31, 2024 and 2023, we recognized $ 0.2 million and $ 0.4 million, respectively, in collaboration revenue from Kyorin for drug product material sold to Kyorin for the Japan portion of the EFZO-FIT study.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch